

## Tumor Profiling

### NGS Panels

Next-generation sequencing for comprehensive mutation analysis

### TMB Assessment

Tumor Mutational Burden predicts immunotherapy response

### MSI Status

Microsatellite Instability as biomarker for treatment selection

### HRD Testing

Homologous Recombination Deficiency guides PARP inhibitor use

PD-L1 Expression: Key biomarker for immune checkpoint inhibitor therapy eligibility